A detailed history of Commonwealth Equity Services, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 34,588 shares of ARWR stock, worth $683,113. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,588
Previous 34,663 0.22%
Holding current value
$683,113
Previous $901,000 25.64%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$19.36 - $29.54 $1,452 - $2,215
-75 Reduced 0.22%
34,588 $670,000
Q2 2024

Jul 31, 2024

BUY
$21.87 - $28.24 $27,337 - $35,300
1,250 Added 3.74%
34,663 $901,000
Q1 2024

Apr 29, 2024

SELL
$27.21 - $39.48 $14,013 - $20,332
-515 Reduced 1.52%
33,413 $956,000
Q4 2023

Feb 06, 2024

SELL
$21.2 - $31.03 $6,656 - $9,743
-314 Reduced 0.92%
33,928 $1.04 Million
Q3 2023

Oct 23, 2023

SELL
$26.2 - $36.08 $3,877 - $5,339
-148 Reduced 0.43%
34,242 $920,000
Q2 2023

Aug 10, 2023

BUY
$25.16 - $41.38 $5,484 - $9,020
218 Added 0.64%
34,390 $1.23 Million
Q1 2023

May 11, 2023

BUY
$23.68 - $38.51 $660,695 - $1.07 Million
27,901 Added 444.92%
34,172 $867,000
Q4 2022

Feb 07, 2023

SELL
$28.0 - $40.56 $6,776 - $9,815
-242 Reduced 3.72%
6,271 $254,000
Q3 2022

Nov 14, 2022

SELL
$29.63 - $48.31 $7,437 - $12,125
-251 Reduced 3.71%
6,513 $215,000
Q2 2022

Jul 19, 2022

BUY
$27.79 - $50.61 $31,013 - $56,480
1,116 Added 19.76%
6,764 $238,000
Q1 2022

May 04, 2022

SELL
$39.62 - $69.97 $22,226 - $39,253
-561 Reduced 9.04%
5,648 $259,000
Q4 2021

Jan 31, 2022

SELL
$58.09 - $82.51 $13,941 - $19,802
-240 Reduced 3.72%
6,209 $411,000
Q3 2021

Oct 29, 2021

SELL
$58.38 - $84.96 $261,834 - $381,045
-4,485 Reduced 41.02%
6,449 $402,000
Q2 2021

Aug 11, 2021

SELL
$62.15 - $90.32 $78,868 - $114,616
-1,269 Reduced 10.4%
10,934 $905,000
Q1 2021

May 04, 2021

SELL
$61.35 - $90.47 $2,147 - $3,166
-35 Reduced 0.29%
12,203 $809,000
Q4 2020

Feb 11, 2021

BUY
$43.82 - $85.37 $10,341 - $20,147
236 Added 1.97%
12,238 $939,000
Q3 2020

Nov 05, 2020

BUY
$33.21 - $51.27 $1,129 - $1,743
34 Added 0.28%
12,002 $516,000
Q2 2020

Aug 12, 2020

BUY
$26.12 - $43.27 $7,914 - $13,110
303 Added 2.6%
11,968 $516,000
Q1 2020

May 11, 2020

SELL
$20.56 - $63.12 $42,662 - $130,974
-2,075 Reduced 15.1%
11,665 $335,000
Q4 2019

Feb 05, 2020

BUY
$28.14 - $73.01 $86,952 - $225,600
3,090 Added 29.01%
13,740 $871,000
Q3 2019

Oct 30, 2019

BUY
$26.26 - $34.86 $26,260 - $34,860
1,000 Added 10.36%
10,650 $300,000
Q2 2019

Jul 19, 2019

SELL
$17.43 - $28.82 $19,783 - $32,710
-1,135 Reduced 10.52%
9,650 $255,000
Q1 2019

May 13, 2019

BUY
$12.05 - $20.18 $129,959 - $217,641
10,785 New
10,785 $197,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.09B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.